Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-Surgical Intramuscular and Intraductal Fulvestrant PK Study
NCT02540330Phase 2Terminated
- Sponsor
- Atossa Therapeutics
- Start
- Mar 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in breast cancer, ductal carcinoma in situ (DCIS), sponsored by Atossa Therapeutics. Started Mar 2016; status: terminated.
02
Drugs
fulvestrant
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on NCT02540330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540330.